KitoZyme Fat-Binding Ingredient Aids Weight Loss in Clinical Study

635709095796796159Kitozyme- KiOnutrime-CsG.jpg

26 Jun 2015 --- Participants in a new clinical study lost an average of 3.2kg in just three months when they consumed KiOnutrime-CsG, a fat-binding ingredient for weight management applications developed by KitoZyme.

The multi-centre, single-blind clinical trial took place at four different hospitals and medical research centres between late 2014 and early 2015. Healthy overweight men and women aged between 18 and 65 were divided into two groups: a treatment group and a control group taking a placebo. Apart from being overweight with a BMI between 26 and 35 at the start of the trial, nobody taking part was suffering from any serious health conditions or was pregnant.

The 64 people in the treatment group were given five capsules per day, each containing 500mg of KiOnutrime-CsG. They took one capsule in the morning, two 15 minutes before lunch and two more 15 minutes before dinner. The 32 people enrolled in the control group followed the same procedure but their capsules contained a placebo. Besides these requirements, everyone continued with their regular diet and exercise patterns and all the participants kept a diary to record their experiences and encourage compliance. Out of 96 people enrolled, a total of 86 people completed the study.

The researchers observed a statistically significant gradual reduction in bodyweight in the treatment group throughout the study, compared with a baseline measured at the start. In contrast, there was no statistically significant change in the body weight of the group who received the placebo. Overall, the subjects in the treatment group lost 3.2kg of their body weight on average over 90 days, compared with the baseline. The researchers also observed statistically significant reductions in average body fat, as well as in the upper abdominal, hip and waist circumference of people consuming KiOnutrime-CsG®.

Francois Luthers, Sales & Marketing Director of KitoZyme, said: “The results of this study, which will be published shortly in a peer-reviewed journal, demonstrate the clear benefits of KiOnutrime-CsG and the significant potential it offers in weight management applications globally.”

Produced by KitoZyme at its manufacturing facility in Belgium, KiOnutrime-CsG works by safely preventing some of the fat in food from being absorbed by the body. It is a cationic (positively charged) biopolymer that binds with anionic (negatively charged) molecules such as fats and fatty acids, and obstructs the emulsification and absorption of cholesterol. Taken just a few minutes before a meal, KiOnutrime-CsG will bind dietary fat in the stomach to form a gel that is later excreted naturally without being absorbed. A previous study carried out using a lab-based model of the human gut showed that KiOnutrime-CsG can bind 42% of the fats ingested in a typical meal.

KiOnutrime-CsG is an animal-free chitosan that is completely odourless and tasteless, making it suitable for a range of applications. It dissolves in just 10 minutes in the acidic environment of the stomach. This means that a dose can be administered almost immediately before a meal, making it convenient and easy for consumers to remember to take. Most other fat binding agents need to be taken up to 30 minutes before a meal, which makes compliance more difficult.

KiOnutrime-CsG is available as an ingredient for dietary supplements in the USA, where the ingredient has GRAS status. In the European Union, it is available from KitoZyme in finished products that are classified as medical devices. KitoZyme offers a range of complete, over-the-counter solutions that are ready to be marketed as own-label or branded products. These include tablets, capsules and sticks. KiOnutrime-CsG is considered safe under the EU’s Novel Foods regulation and is already approved by the European Food Safety Authority (EFSA) to carry the health claim that it maintains normal blood LDL cholesterol at a dose of 3g per day.

To contact our editorial team please email us at

Related Articles

Health & Nutrition News

EMA: Omega 3 fatty acid medicines no longer seen as effective in preventing heart disease

17 Dec 2018 --- The European Medicines Agency (EMA) has concluded that medicines containing omega 3 fatty acids are not effective in preventing further heart and blood vessel problems in patients who have had a heart attack. As a result of this finding, omega 3 fatty acid medicines will no longer be authorized for such use. These types of medicines had been authorized for use after a heart attack at a dose of 1g per day, in combination with other medicines, in several EU countries since 2000.

Health & Nutrition News

Eisai enters deal with Eurofarma for its “holy grail” weight-loss agent for the Brazilian market

17 Dec 2018 --- Eisai has granted Brazilian pharmaceutical company Eurofarma the exclusive marketing and development rights for lorcaserin, an anti-obesity agent, in Brazil. Eisai reports the move will provide the means to leverage Eurofarma’s strong business foundation throughout Latin America to accelerate the delivery of lorcaserin to more patients.

Health & Nutrition News

DuPont Nutrition & Health synbiotic touted to reduce health risks linked to obesity

14 Dec 2018 --- DuPont Nutrition & Health’s Howaru Shape synbiotic may help reduce health risks for overweight consumers, according to a recent clinical study on synbiotic dietary supplements. Howaru Shape combines the benefits of a probiotic with prebiotic fiber and is touted as capable of improving metabolic health and promoting weight loss.

Health & Nutrition News

Rousselot targets sports nutrition segment with collagen peptides ingredient

13 Dec 2018 --- Supplementation with the collagen peptide Peptan before and after intense exercise can reduce muscle damage, research led by Rousselot has found. Conducted with Newcastle University researchers in the UK, the study shows how the collagen ingredient can help repair connective tissues after physical activity, thereby preventing the risk of injury when used as a food supplement in sports nutrition. As the first clinical study showing the beneficial effects of collagen peptides for exercise recovery, the findings support the ingredient’s positioning as suitable for sports nutrition.

Health & Nutrition News

Red meat and heart disease risk: Researchers identify mechanisms involving gut bacteria

11 Dec 2018 --- New mechanisms that demonstrate how the regular consumption of red meat is linked to increased chances of heart-related diseases and how gut bacteria affect the process have been published. Concurrent studies carried out at the Cleveland Clinic Center for Microbiome and Human Health have discovered note the difference between red meat and other protein source consumption on the development of heart disease.

More Articles